Protara Therapeutics (TARA) Financials

Protara Therapeutics remains a pre-revenue biotechnology company with substantial liquidity but continued operating losses. The company reported no revenue in any of the periods provided, while research and development spending has increased as its pipeline advances. As of June 30, 2026, Protara had $17.1 million in cash, $125.4 million in short-term investments and $19.4 million in long-term investments, providing a sizable liquid asset base relative to its $14.8 million of total liabilities.

• Strong balance-sheet liquidity: Cash, short-term investments and long-term investments totaled approximately $159.7 million at the end of Q2 2026. This compares with roughly $73.0 million in cash and short-term investments in Q3 2023, although the balance has declined from $177.8 million at the end of Q1 2026.
• Low leverage: Total liabilities were $14.8 million in Q2 2026 versus $161.3 million of equity. The company has no preferred stock and no reported commitments or contingencies, which limits near-term balance-sheet leverage.
• Interest income is providing some support: Interest and investment income was $1.7 million in Q2 2026 and $3.5 million during the first half of 2026. This income partially offsets operating expenses while Protara’s investment portfolio remains substantial.
• Quarterly cash flow improved sequentially: Net cash used in operating activities narrowed to $15.4 million in Q2 2026 from $21.3 million in Q1. Investment maturities and sales also produced $37.3 million of cash in Q2, allowing the company to report a $2.3 million increase in cash for the quarter despite ongoing operating losses.
• R&D investment is increasing: Research and development expense rose to $17.0 million in Q2 2026 from $13.6 million in Q1 and $10.8 million in Q2 2025. For a development-stage biotechnology company, higher R&D spending may indicate increased investment in clinical and pipeline activities, although it also raises the cash required to reach potential commercialization.

The company’s liquidity is offset by a persistent cash-burn profile. Operating cash outflows were $14.7 million in Q1 2024, $15.0 million in Q1 2025 and $21.3 million in Q1 2026 before improving to $15.4 million in Q2 2026. The first half of 2026 therefore consumed approximately $36.7 million in operating cash. At the Q2 spending rate, the current liquid asset base appears meaningful, but the duration of that funding will depend on clinical spending, investment returns and any future financing.

• Investment portfolio activity is driving reported cash changes: Protara has repeatedly purchased and sold or matured investments. In Q2 2026, $37.3 million of investment sales and maturities more than offset $19.2 million of purchases. These transactions improve short-term cash flexibility but are not recurring operating revenue.
• Equity financing has supported the balance sheet: Financing activity included approximately $42.1 million of common-equity issuance in Q2 2024 and approximately $81.8 million in Q4 2025. These financings helped build the company’s cash and investment position, but they also contributed to a substantial increase in shares outstanding.
• Current assets remain well above current liabilities: Q2 2026 current assets were $146.2 million compared with $13.3 million of current liabilities. This indicates considerable short-term financial flexibility, though most current assets are investments rather than cash generated by operations.

Profitability remains the primary weakness. Revenue has been reported at zero throughout the provided periods, leaving Protara dependent on its capital base and financing activities. Net losses widened from $11.1 million in Q1 2024 to $21.7 million in Q2 2026. The Q2 2026 loss also increased from $17.8 million in Q1, while total operating expenses rose to $23.3 million from $19.6 million in Q1.

• No operating revenue: Protara reported zero revenue and zero gross profit in every income statement period provided. The company has not yet demonstrated commercial sales or an operating revenue stream to fund research and development.
• Losses and operating expenses are trending higher: Q2 2026 operating expenses of $23.3 million were approximately 22% higher than Q1 2026 and 41% higher than Q2 2025. The resulting net loss was $21.7 million, compared with $14.96 million in Q2 2025.
• Persistent negative operating cash flow: Protara has used cash in operations in every cash-flow period supplied. Investment sales and equity offerings have periodically offset that burn, but those sources do not indicate that the underlying business is self-funding.
• Shareholder dilution is significant: Weighted-average basic shares increased from approximately 20.6 million in Q3 2023 to 61.0 million in Q2 2026. Future capital raises could further dilute existing shareholders if operating cash flow remains negative.
• Accumulated losses continue to grow: Retained earnings declined to negative $341.9 million at June 30, 2026, from negative $211.5 million at March 31, 2024. This reflects the company’s long-term history of losses and highlights the need for successful clinical development or eventual commercialization.

Overall, Protara’s financial statements show a company with a relatively strong, lightly leveraged balance sheet but no current operating revenue and a growing cost base. The key investor questions are whether increased R&D spending can advance the pipeline, how quickly the remaining liquidity is consumed, and whether additional equity financing will be required before the company can generate product revenue.